ISABEL MANUELA
ÁLVAREZ LÓPEZ
Hospital Miguel Servet
Zaragoza, EspañaPublications in collaboration with researchers from Hospital Miguel Servet (10)
2023
-
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry
Breast Cancer Research and Treatment, Vol. 201, Núm. 2, pp. 151-159
2022
2021
-
Early imaging and molecular changes with neoadjuvant bevacizumab in stage ii/iii breast cancer
Cancers, Vol. 13, Núm. 14
-
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499
2018
2017
-
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624
2013
2012
-
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: Final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial
Cancer, Vol. 118, Núm. 1, pp. 241-247
-
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers
BMC Medical Genomics, Vol. 5
2008
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814